Follow
Tumor Microenvironment
Tumor Microenvironment: is the cellular environment in which non-cancerous cells are present in the tumor. This environment including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules and the extracellular matrix .
-
OCT 30, 2014 | 3:00 PM
Oncogenic mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) compromise their normal activity and induce NADPH-dependent (D)2-hydroxyglutarate (2HG) production within the cytosol or m...Speaker: Christian Metallo, PhDOCT 30, 2014 | 12:00 PM
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...Speaker: Julian J. Lum, PhDOCT 29, 2014 | 12:00 PM
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...Speaker: Liza Makowski, PhD
OCT 17, 2013 | 1:00 PM
C.E. CREDITS
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Speaker:
Milan Radovich, PhD
OCT 17, 2013 | 12:00 PM
C.E. CREDITS
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Speaker:
Daniel Irimia, MD, PhD
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
Speaker:
George Poste, DVM, DSc, PhD
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
Speaker:
Andrew Armstrong, MD ScM FACP
OCT 30, 2014 | 3:00 PM
Oncogenic mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) compromise their normal activity and induce NADPH-dependent (D)2-hydroxyglutarate (2HG) production within the cytosol or m...
Speaker:
Christian Metallo, PhD
OCT 30, 2014 | 12:00 PM
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...
Speaker:
Julian J. Lum, PhD
OCT 29, 2014 | 12:00 PM
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer (BBC). Using C3(1)-TAg mice, a genetically engineered mouse model that resembles human BBC, w...
Speaker:
Liza Makowski, PhD
OCT 17, 2013 | 1:00 PM
C.E. CREDITS
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Speaker:
Milan Radovich, PhD
OCT 17, 2013 | 12:00 PM
C.E. CREDITS
Invading cancer cells leave the tumor to form distant metastases and are ultimately responsible for 90% of deaths in cancer. Reducing the ability of cancer cells to invade and metastasize cou...
Speaker:
Daniel Irimia, MD, PhD
OCT 17, 2013 | 11:00 AM
C.E. CREDITS
Curative therapy for metastatic disease in solid malignancies remains frustratingly elusive due to the long recognized problem of tumor cell heterogeneity and emergence of treatment resistant...
Speaker:
George Poste, DVM, DSc, PhD
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
Speaker:
Andrew Armstrong, MD ScM FACP